{"text_format":"2","workbook":"xls","n_sheets":1,"sheets":["report2"],"not_rendered":{"charts":0,"images":0,"macros":0,"external_links":1,"defined_names":2,"comments":0,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"run_cost":"one","rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900","formulas":"cached_only"}

{"sheet":"report2","index":0,"n_rows":57,"n_cols":5,"rows_kept":57,"cut":false,"hidden":false,"merged":[[0,2,0,3],[0,4,0,5],[1,2,1,3],[1,4,1,5],[2,2,2,3],[2,4,2,5],[3,2,3,3],[4,2,4,3],[14,2,14,3],[15,2,15,3],[16,2,16,3],[17,2,17,3],[21,2,21,3],[22,2,22,3],[26,2,26,3],[29,2,29,3],[29,4,29,5],[30,2,30,3],[30,4,30,5],[31,2,31,3],[31,4,31,5],[32,2,32,3],[33,2,33,3],[38,2,38,3],[39,2,39,3],[40,2,40,3],[42,2,42,3],[44,2,44,3],[45,2,45,3],[49,2,49,3]],"flags":["formulas_cached_only"]}
[null,"1.","Record Nr.",null,"UNINA9910461445503321"]
[null,null,"Autore",null,"DuBois Thomas David <1969->"]
[null,null,"Titolo",null,"Religion and the making of modern East Asia / / Thomas David DuBois [[electronic resource]]"]
[null,null,"Pubbl/distr/stampa",null,"Cambridge : , : Cambridge University Press, , 2011"]
[null,null,"ISBN",null,"1-139-06408-8"]
[{"$nulls":4},"1-107-22189-7"]
[{"$nulls":4},"1-283-11117-9"]
[{"$nulls":4},"9786613111173"]
[{"$nulls":4},"1-139-07658-2"]
[{"$nulls":4},"0-511-97707-7"]
[{"$nulls":4},"1-139-08340-6"]
[{"$nulls":4},"1-139-07086-X"]
[{"$nulls":4},"1-139-08113-6"]
[{"$nulls":4},"1-139-07886-0"]
[null,null,"Descrizione fisica",null,"1 online resource (xii, 259 pages) : digital, PDF file(s)"]
[null,null,"Collana",null,"New approaches to Asian history ; ; 8"]
[null,null,"Disciplina",null,"200.951"]
[null,null,"Soggetti",null,"Buddhism - Japan - History"]
[{"$nulls":4},"Confucianism - China - History"]
[{"$nulls":4},"Japan Religion"]
[{"$nulls":4},"China Religion"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Title from publisher's bibliographic system (viewed on 05 Oct 2015)."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"In the beginning: religion and history -- Ming China: the fourteenth century's new world order -- The Buddha and the shogun in sixteenth-century Japan -- Opportunities lost: the failure of Christianity, 1550-1750 -- Buddhism: incarnations and reincarnations -- Apocalypse now -- Out of the twilight: religion and the late nineteenth century -- Into the abyss: religion and the road to disaster during the early twentieth century -- Brave new world : religion in the reinvention of postwar Asia -- The globalization of Asian religion."]
[null,null,null,"Sommario/riassunto","Religious ideas and actors have shaped Asian cultural practices for millennia and have played a decisive role in charting the course of its history. In this engaging and informative book, Thomas David DuBois sets out to explain how religion has influenced the political, social, and economic transformation of Asia from the fourteenth century to the "]
[{"$nulls":4},"present. Crossing a broad terrain from Tokyo to Tibet, the book highlights long-term trends and key moments, such as the expulsion of Catholic missionaries from Japan, or the Taiping Rebellion in China, when religion dramatically transformed the political fate of a nation. Contemporary chapters reflect on the wartime deification of the Japanese emperor, Marxism as religion, the persecution of the Dalai Lama, and the fate of Asian religion in a globalized world."]
[null,"2.","Record Nr.",null,"UNINA9910829980403321"]
[null,null,"Autore",null,"Ellenberg Susan Smith"]
[null,null,"Titolo",null,"Data monitoring committees in clinical trials [[electronic resource] ] : a practical perspective / / Susan S. Ellenberg, Thomas R. Fleming, David L. DeMets"]
[null,null,"Pubbl/distr/stampa",null,"Chichester ; ; Hoboken, NJ, : Wiley, c2002"]
[null,null,"ISBN",null,"1-280-26999-5"]
[{"$nulls":4},"9786610269990"]
[{"$nulls":4},"0-470-32228-4"]
[{"$nulls":4},"0-470-85415-4"]
[{"$nulls":4},"0-470-85416-2"]
[null,null,"Descrizione fisica",null,"1 online resource (209 p.)"]
[null,null,"Collana",null,"Statistics in practice"]
[null,null,"Disciplina",null,"610/.72/4"]
[{"$nulls":4},"615.190072"]
[null,null,"Soggetti",null,"Clinical trials"]
[{"$nulls":4},"Medical ethics committees"]
[null,null,"Lingua di pubblicazione",null,"Inglese"]
[null,null,"Formato",null,"Materiale a stampa"]
[null,null,null,"Livello bibliografico","Monografia"]
[null,null,null,"Note generali","Description based upon print version of record."]
[null,null,null,"Nota di bibliografia","Includes bibliographical references and index."]
[null,null,"Nota di contenuto",null,"Data Monitoring Committees in Clinical Trials A Practical Perspective; Contents; Preface; 1 Introduction; 1.1 Motivation; 1.2 History of data monitoring committees in government-sponsored trials; 1.3 Data monitoring committees in trials sponsored by the pharmaceutical industry; 1.4 Statistical methods for interim monitoring; 1.5 When are data monitoring committees needed?; 1.6 Where we are today; 1.7 Fundamental principles of data monitoring; References; 2 Responsibilities of the data monitoring committee and motivating illustrations; 2.1 Fundamental charges"]
[{"$nulls":4},"2.2 Specific tasks of the data monitoring committee 2.2.1 Initial review; 2.2.1.1 Review of the study protocol; 2.2.1.2 Review of procedures to ensure quality of study conduct; 2.2.2 Evaluating the quality of ongoing study conduct; 2.2.3 Assessing safety and efficacy data; 2.2.3.1 Termination due to favorable benefit-to-risk; 2.2.3.2 Termination due to unfavorable benefit-to-risk; 2.2.3.3 Termination due to inability to answer trial questions; 2.2.3.4 Continuation of ongoing clinical trials; 2.2.3.5 Consideration of the overall picture: primary and secondary analyses"]
[{"$nulls":4},"2.2.3.6 Modifying sample sizes based on ongoing assessment of event "]
[{"$nulls":4},"rates 2.2.4 Reviewing the final results; 2.3 The data monitoring committee charter; References; 3 Composition of a data monitoring committee; 3.1 Introduction; 3.2 Required areas of expertise; 3.3 Other relevant characteristics of committee members; 3.4 Committee size; 3.5 Selecting the committee chair; 3.6 Responsibility for appointing committee members; 3.7 Representation of other study components on the committee; 3.8 Preparation for service on a committee; References"]
[{"$nulls":4},"4 Independence of the data monitoring committee: avoiding conflicts of interest 4.1 Introduction; 4.2 Rationale for independence; 4.3 Financial independence; 4.3.1 Sponsors; 4.3.2 Academic investigators; 4.4 Intellectual independence; 4.5 Emotional conflicts; 4.6 Individuals without conflicts; References; 5 Confidentiality issues relating to the data monitoring committee; 5.1 Rationale; 5.2 Limits of confidentiality; 5.2.1 Interim analysis reports; 5.2.2 Access to aggregate data on efficacy and safety outcomes; 5.2.3 The steering committee and maintaining confidentiality"]
[{"$nulls":4},"5.2.4 Settings and procedures allowing broader unblinding 5.2.5 Some illustrations of broader unblinding; 5.2.6 Indirect challenges to confidentiality; 5.3 The need for the data monitoring committee to review unblinded data; References; 6 Data monitoring committee meetings; 6.1 Introduction; 6.2 Specific objectives and timing of meetings; 6.2.1 Organizational meeting; 6.2.2 Early safety/trial integrity reviews; 6.2.3 Formal interim efficacy analyses; 6.2.4 End-of-trial debriefing; 6.3 Preparation of meeting reports; 6.4 Format for meetings; 6.4.1 The closed session; 6.4.2 The open session"]
[{"$nulls":4},"6.4.3 The final closed session"]
[null,null,null,"Sommario/riassunto","There has been substantial growth in the use of data monitoring committees in recent years, by both government agencies and the pharmaceutical industry. This growth has been brought about by increasing recognition of the value of such committees in safeguarding trial participants as well as protecting trial integrity and the validity of conclusions. This very timely book describes the operation of data monitoring committees, and provides an authoritative guide to their establishment, purpose and responsibilities.* Provides a practical overview of data monitoring in clinical trials.*"]